UROLITHIN GUMMY (PECTIN) FORMULATIONS
The invention relates to composition of urolithins comprising urolithins and pectin and formulations of urolithins, specifically chewable formulations, comprising urolithins and a gelling agent. The invention further comprises compositions and chewable formulations comprising urolithins in combination with other active ingredients and processes for the preparation of such compositions and formulations. The invention further comprises methods of using such compositions and formulations in the treatment of conditions and diseases and for the promotion of health and performance, such in the improving muscle function.
1 . A composition comprising:
a. a compound of formula (I) or a salt thereof:
wherein:
A, B, C and D are each independently selected from H and OH;
W, X and Y are each independently selected from H and OH; and
Z is selected from H and OH; and
b. pectin.
2 . The composition as claimed in claim 1 wherein the pectin is selected from low methoxy pectin, high methoxy pectin or amidated low methoxy-pectin, or a mixture thereof, for example, wherein the pectin is high methoxypectin.
3 . The composition as claimed in claim 1 , wherein the compound of Formula (I) and pectin are in the ratio 1 to about 1 to 1 to about 10 (w/w).
4 . The composition as claimed in claim 1 , wherein the composition is a gummy.
5 . The composition as claimed in claim 1 , wherein the composition is a powder.
6 . (canceled)
7 . The composition as claimed in claim 1 , wherein the composition is prepared by spray drying.
8 . The composition as claimed in claim 1 , wherein the compound of Formula (I) is in amorphous form or partially in amorphous form.
9 . (canceled)
10 . The composition as claimed in claim 1 , further comprising one or more of the following:
a) soluble fibre, for example, soluble tapioca fibre;
b) a low calorie sweetener, for example, allulose; and
c) citric acid and/or a citrate salt (for example, sodium citrate), for example, citric acid and a salt of citric acid (for example, sodium citrate).
11 . The composition as claimed in claim 1 , comprising:
a) about 5% to about 20% (w/w) of a compound of formula (I); for example, urolithin A; and
b) about 0.5% to about 4% (w/w) pectin;
and further comprising one or more of the following
c) about 25% to about 45% (w/w) soluble fibre, for example, soluble tapioca fibre;
d) about 25% to about 45% (w/w) of a low calorie sweetener, for example, allulose; and
e) about 0.5% to about 4% (w/w) citric acid and/or a citrate salt (for example, sodium citrate), for example, citric acid and a salt of citric acid (for example, sodium citrate).
12 . A chewable formulation comprising:
a) a gelling component,
b) a compound of formula (I) or a salt thereof:
wherein:
A, B, C and D are each independently selected from H and OH;
W, X and Y are each independently selected from H and OH; and
Z is selected from H and OH.
13 . The chewable formulation, as claimed in claim 12 , further comprising:
c) a sweetener system, for example, wherein the sweetener system comprises one or more sweeteners.
14 . The chewable formulation, as claimed in claim 12 , wherein the gelling component comprises one or more of the following: pectin, gelatine, and modified starch.
15 . The chewable formulation, as claimed in claim 12 , wherein the gelling component comprises high methoxy pectin having an esterification range of about 50% to about 75%.
16 . (canceled)
17 . The chewable formulation, as claimed in claim 12 , wherein the formulation comprises about 0.5% to about 5% (w/w) gelling component, for example about 0.5% to about 4% (w/w) pectin, such as about 1.5% to about 3% (w/w) pectin.
18 . The chewable formulation, as claimed in claim 12 , further comprising:
d) a fibre component, for example, a soluble fibre component.
19 . (canceled)
20 . The chewable formulation as claimed in claim 12 , wherein the formulation has a brix between about 75 degrees to about 85 degrees.
21 . (canceled)
22 . (canceled)
23 . The composition as claimed in claim 1 , wherein the compound of Formula (I) is selected from urolithin A, urolithin B, urolithin C or urolithin D, for example, urolithin A.
24 . (canceled)
25 . The composition as claimed in claim 1 formulated as a medicament, dietary supplement, functional food or medical food.
26 . A method for the treatment and/or prophylaxis of a muscle-related pathological condition, for example, wherein the muscle-related pathological condition is selected from musculoskeletal diseases or disorders; muscle wasting; myopathies;
neuromuscular diseases, such as Duchenne muscular dystrophy and other dystrophies;
sarcopenia, for example, acute sarcopenia; muscle atrophy and/or cachexia, comprising administering to a subject in need thereof an effective amount of a composition as claimed in claim 1 .
27 . A method of enhancing muscle performance, of improving endurance capacity, or of improving, maintaining or reducing the loss of muscle function; or of improving physical performance or physical endurance; or of increasing muscle strength, increasing or maintaining muscle mass, or improving muscle recovery; or of inhibiting or retarding physical fatigue, enhancing working capacity and endurance, reducing muscle fatigue, or enhancing cardiac and cardiovascular function; or of enhancing sports performance; or of improving non disease health conditions characterized by inadequate mitochondrial activity; or of enhancing healthspan, comprising administering to a subject in need thereof an effective amount of a composition as claimed in claim 1 .
28 . (canceled)
29 . (canceled)
30 . (canceled)
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . (canceled)
35 . (canceled)